Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. FFAI
9. TRMD
10. ACN

Go back to Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
(NYSE: PRTO) Delayed: 27.63 +0.01 (0.04%)
Previous Close $27.62    52 Week High $16.48 
Open $27.56    52 Week Low $4.90 
Day High $27.63    P/E N/A 
Day Low $27.56    EPS $0.00 
Volume 419